{"paper_id":"0754b324-0b60-4e13-8340-705ea9b99ad7","body_text":"Literatur\nPatel BG, Rudnicki M, Yu J, Shu Y, Taylor RN (2017) Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand 96(6):623–632\nMarquardt RM, Kim TH, Shin JH, Jeong JW (2019) Progesterone and estrogen signaling in the endometrium: what goes wrong in endometriosis? IJMS 20(15):3822\nBulun SE (2009) Endometriosis. N Engl J Med 360(3):268–279\nHarrison RF, Barry-Kinsella C (2000) Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 74(1):24–30\nVercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG (2002) Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 77(1):52–61\nMorotti M, Venturini PL, Biscaldi E et al (2017) Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. Eur J Obstet Gynecol Reprod Biol 213:4–10\nTanmahasamut P, Saejong R, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Sanga-Areekul N (2017) Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecol Endocrinol 33(7):534–539\nLang J, Yu Q, Zhang S et al (2018) Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study. J Womens Health 27(2):148–155\nYu Q, Zhang S, Li H et al (2019) Dienogest for treatment of endometriosis in women: a 28-week, open-label, extension study. J Womens Health 28(2):170–177\nStrowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25(3):633–641\nHarada T, Kosaka S, Elliesen J, Yasuda M, Ito M, Momoeda M (2017) Ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril 108(5):798–805\nYamanaka A, Hada T, Matsumoto T et al (2017) Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis. Eur J Obstet Gynecol Reprod Biol 216:51–55\nChen YJ, Hsu TF, Huang BS, Tsai HW, Chang YH, Wang PH (2017) Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol 216(6):582.e1–582.e9\nCho S, Jung JA, Lee Y et al (2014) Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gynecol Scand 93(1):38–44\nMorelli M, Sacchinelli A, Venturella R, Mocciaro R, Zullo F (2013) Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J Obstet Gynaecol Res 39(5):985–990\nCarr B, Dmowski WP, O’Brien C et al (2014) Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 21(11):1341–1351\nFlores VA, Vanhie A, Dang T, Taylor HS (2018) Progesterone receptor status predicts response to progestin therapy in endometriosis. J Clin Endocrinol Metab 103(12):4561–4568\nMaiorana A, Incandela D, Parazzini F et al (2017) Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch Gynecol Obstet 296(3):429–433\nVercellini P, Bracco B, Mosconi P et al (2016) Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 105(3):734–743.e3\nReis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C, Petraglia F (2020) Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update 26(4):565–585\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nInteressenkonflikt\nQ. Le, S. Franik, L. Kiesel und S.D. Schäfer geben an, dass kein Interessenkonflikt besteht.\nFür diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.\nAdditional information\nRedaktion\nA. Bachmann, Frankfurt\nL. Kiesel, Münster\nP. Stute, Bern\nRights and permissions\nAbout this article\nCite this article\nLe, Q., Franik, S., Kiesel, L. et al. Hormonresistenz in der medikamentösen Therapie der Endometriose. Gynäkologische Endokrinologie 18, 252–257 (2020). https://doi.org/10.1007/s10304-020-00346-7\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s10304-020-00346-7","source_license":"CC0","license_restricted":false}